Refractory Multiple Myeloma: 1455 Clinical Trials, Page 145 of 146

Hide Studies Not Open or Pending


Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Condition(s):Non Hodgkin Lymphoma; Richter Transformation; Multiple Myeloma; T-cell-prolymphocytic Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myeodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myelofibrosis; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Chronic Myelomonocytic Leukemia-2; Myelodysplastic Neoplasm in Blast PhaseLast Updated:October 12, 2022Recruiting

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.